$VICR

Davies Philip D sold $5K of VICR

Davies Philip D (VP Global Sales & Marketing) sold 17 shares of VICOR CORP (VICR) at $317.85 on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Davies Philip D
Published Jun 2, 2026, 2:11 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 2, 2026, 2:15 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$VICR
Neutral
high confidence
Mentioned
$VICR
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VICRNeutralLow
01

Why it matters

Given the scheduled nature and small dollar amount, the filing is more relevant for monitoring insider activity than for forecasting fundamentals.

02

Market read

A small, scheduled insider sale is unlikely to drive a sustained repricing without additional company news.

03

What to watch

The sale size is small ($5.4K) and explicitly pre-arranged, reducing interpretive weight versus unscheduled or larger transactions.

Relevance 6/10Novelty 2/10Timing: Filed 2026-06-02 after the 2026-06-01 sale execution.

Background

SEC Form 4 reports insider trades; a 10b5-1 plan indicates the trades were pre-scheduled to reduce timing-based insider-trading concerns.

Company-level read

Ticker impact

$VICRNeutralHigh confidence
Context

VICR disclosed an officer/director open-market sale: 17 shares sold on 2026-06-01 at $317.8476 under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any reaction should fade unless accompanied by other company-specific news.

Evidence & confidence

The filing is a small, scheduled sale (10b5-1) by a sales/marketing VP, with no new operational or financial disclosure.

Market effects

No clear sector read-through; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

Even scheduled 10b5-1 sales can coincide with internal caution; traders may still use it as a minor sentiment check.

Key entities

  • VICOR CORP

    Subject of the insider transaction disclosure (Form 4) for an officer/director sale under a 10b5-1 plan.

  • Davies Philip D

    VP Global Sales & Marketing; sold 17 shares on 2026-06-01.

Related articles

$VICRMedAI 8/10

Vicor (VICR) Q2 2026 Earnings Call Transcript

Vicor’s Q2 2026 earnings call reported product and royalty revenue of $143.4M, up 26.9% sequentially and 1.6% year over year. Advanced products revenue rose to $94.2M. Net income was $49.8M, GAAP diluted EPS $1.40, and cash was $453.6M. The company guided for nearly 10% Q3 revenue growth and over $600M 2026 revenue, citing capacity increases and licensing assumptions.

$VICRMed

Vicor Corp (VICR) Q2 2026 Earnings Call Highlights: Strong Revenue Growth

Vicor Corp said a new license agreement will bring $5 million quarterly payments in year one and $10 million in year two, with $15 million contributing to Q2 revenue and additional revenue recognition expected in Q3 and subsequent quarters. Management also discussed fab capacity expansion to support a $2.5 billion revenue goal and said backlog growth stems mainly from existing customer demand.

$VICRMed

VICOR CORP (VICR): Results of Operations and Financial Condition

VICOR CORP (VICR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d115827dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 NEWS RELEASE FINANCIAL NEWS BRIEF July 21, 2026 For Immediate Release Vicor Corporation Reports Results for the Second Quarter Ended June 30, 2026 Andover, Mass., July 21, 2026 (GLOBE NEWSWIRE) — Vicor Corporation (NASDAQ: